AUTL Stock Price
Autolus Therapeutics plc
AUTL stock price is $1.69 (+4.32% on the day), giving Autolus Therapeutics plc a market cap of $449.81M. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
AUTL Stock Overview
- Price
- $1.69
- Previous close
- $1.62
- Open
- $1.61
- Market cap
- $449.81M
- P/E ratio
- -2.0
- 52-week range
- $1.18 - $2.58
- 1-year price target
- $8.69
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NGS
- MarketXLS Rank
- 39
About Autolus Therapeutics plc
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AUTL | $1.69 | +4.3% | 2.58M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Autolus Therapeutics plc Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW